Hvivo Share Discussion Threads

[chica1] 01/10/2024 12:32

Whooping cough Challenge trials


Tests of new vaccines have been difficult, however, because whooping cough cycles, with major outbreaks every three to five years, and researchers can’t predict where or when it will surge. Manufacturers need large numbers of infected people to test their inoculations.

Enter human challenge studies.

In some ways, whooping cough is an ideal infection to test in human challenge models. It’s curable with antibiotics in its early stages, which protects study volunteers from harm.

On the other hand, most people have few symptoms in those early stages. Investigators can measure the vaccine’s ability to prevent mild early symptoms and whether it can prevent bacteria from setting up shop in nasal passages, but the pertussis challenge models don’t allow them to directly measure how well a vaccine may prevent severe disease, which is the goal of most vaccines.

Researchers also don’t know what immune factors may indicate that a person is protected from whooping cough, so they can’t measure whether people are getting protection that’s at least as good as that provided by the approved vaccines, a strategy called bridging.

Get CNN Health's weekly newsletter
Sign up here to get The Results Are In with Dr. Sanjay Gupta every Friday from the CNN Health team.
On Friday, labs in Canada and the UK presented their models for how to conduct challenge trials for pertussis.

The FDA advisers were then asked whether they thought these kinds of trials could measure the right things and, if so, if they would provide enough evidence to be the basis of a vaccine approval.

The labs’ models were met with mixed reactions from the experts. On the one hand, they said, this approach was exciting and would surely speed the testing of new vaccines. On the other hand, they weren’t sure these studies had been fine-tuned enough.

“I’m very supportive of this; whether or not we are quite there yet, I’m not totally sure,” said Dr. Melinda Wharton, associate director for vaccine policy and clinical partnerships at the CDC’s National Center for Immunization and Respiratory Diseases.

[chica1] 01/10/2024 12:24

Peel Hunt

www.proactiveinvestors.co.uk/companies/news/1057336/analysts-remain-impressed-by-hvivo-s-expanding-clinical-offerings-1057336.html


Analysts at broker Peel Hunt remain impressed by hVIVO PLC's (AIM:HVO) unique offering in the human challenge trial segment and the rapid diversification of its services.

The broker's view comes in light of hVIVO’s launch of the full suite of its hLAB standalone services, expanding its virology and immunology laboratory offerings.

hVIVO’s new Canary Wharf facility features a new CL-3 laboratory, allowing work with hazard group 3 pathogens.

hLAB has also expanded its assay portfolio to include services for a range of new pathogens, including Omicron, Bordetella pertussis, and various strains of influenza, among others.

“This positions hVIVO as a potential specialised full-service CRO (contract research organisation) of scale,” said Peel Hunt.

“While we do not expect these new services to significantly impact FY24E forecasts, the development of additional contracts and services, such as field challenge trials and hLAB, presents potential upside risk to the mid- to long-term revenue guidance of £100m by 2028.”

[chica1] 01/10/2024 12:00

Me thinks some Institutions are going to get it cheaper.

We need something!

[sikhthetech] 30/9/2024 16:24

There you go readers..

1gw, the mega hypocrite and BS.

INSE... IIs dumping, huge voting against AGM resolutions, share price crashes.
Yet despite the IIs dumping and huge voting against AGM resolutions, 1gw and mates are ramping the shares.




1gw portrays himself as a well researched, reasoned poster. Yet virtually all his/his mates shares crash. Byot down 99.9%, rthm down 80%, trmr down 80%, Inse down 50%

1gw makes a dodgy 2nd hand car salesman sound honest.

How many multiple ids do you use, 1gw and why?

[sikhthetech] 30/9/2024 16:18

1gw,

"Having reported 1.2m shares at end May, they're showing 6.6m shares at end June."

How does that 'big' 5m increase compare to the huge >7m options awarded to the CEO last year, backdated a year and which start to exercise in just 4 months time?


"End of June."

How does that compare to the Chairman dumping his entire holding just 4 working days after the July TU and investor presentation?

I think the chairman knows more about the company than any II or PI. Do you?


Talking about II holdings.
TLY has c40% II holding, the chairman, CFO and other directors have been buying, yet you are ignoring the huge II holding there. You're even dismissing the £6m contracts they announced last week. Hypocrite depending what will pull the wool over PIs eyes!!!

[1gw] 30/9/2024 12:03

Good to see a big increase in TM Tellworth's (Premier Miton) holding in June, according to Morningstar. Having reported 1.2m shares at end May, they're showing 6.6m shares at end June.



--------------------------------
1gw - 03 Sep 2024 - 11:21:02 - 7888 of 8160 hVIVO plc - HVO

Institutional Ownership.

From the Morningstar data, it looks like we have another relatively new smallcap fund owner, with TM Tellworth UK Smaller Companies showing 1.2m shares as of 31st May.

TM Tellworth is part of Premier Miton, as of January this year.

Nice to see that there are now (according to the Morningstar data) 20 individual funds each holding more than 1m shares of HVO.

[chica1] 30/9/2024 08:35

Blackhorse we're trading at 2.5 times revenue our peers are trading at 3 plus times..

[blackhorse23] 30/9/2024 08:17

Mcap too high , it's overpriced

[pogue] 30/9/2024 07:28

and there it is the database being put to work, all in the RNS and previous presentation. Another income stream ontop of the labs.

[burtond1] 30/9/2024 06:46

Exciting news for hVIVO today as we announced the official launch of our full suite of hLAB standalone virology & immunology laboratory services for preclinical & clinical drug development. You can read the full announcement here: https://www.londonstockexchange.com/news-article/HVO/launch-of-full-suite-of-hlab-standalone-services/16689239 hLAB is an industry leader in virology and clinical trial support and has been providing lab services since 1989. However due to the growing demand for hVIVO's world leading human challenge trial services, hLAB has been at capacity facilitating the delivery of these trials. Following the move to the new facility at Canary Wharf, we have tripled laboratory capacity facilitating an expansion of our service offering. The expanded laboratory space has been specifically designed to streamline workflows and provide operational efficiencies. It includes a cutting-edge CL-3 laboratory, allowing hVIVO to work with hazard group 3 pathogens. The CL-3 lab has now received HSE clearance, and has commenced operations. hLAB has also launched its biobank services and has been approved by the UK Research Ethics Committee as a Research Tissue Bank. The biobank is a comprehensive repository of a diverse range of human biofluids, providing researchers with a valuable resource to drive innovation, with a particular focus on vaccine development, immunology, and respiratory research.You can learn more about hLAB's service offering here: hlabservices.com

[supernumerary] 26/9/2024 17:43

And Enanta seems happy with the results of its challenge trial:



Enanta's RSV antiviral crushes viral load in challenge study

Enanta Pharmaceuticals has linked its respiratory syncytial virus (RSV) antiviral to significant reductions in viral load and symptoms in a phase 2a challenge study. The biotech said the results cleared the bar set by its other candidate, opening up opportunities to test the molecules as single agents and in combination.

Previously, Enanta reported data from a challenge study of its N-protein inhibitor zelicapavir. The data led to further development of the candidate. In parallel, Enanta advanced a L-protein inhibitor, EDP-323. The EDP-323 challenge study had essentially the same design as the zelicapavir trial and was run at the same location, potentially allowing Enanta to make a more accurate comparison than is typically possible.

Scott Rottinghaus, M.D., chief medical officer at Enanta, said in a statement that the EDP-323 data raise “the high bar set by zelicapavir.” In a study of 142 healthy adults inoculated with RSV, EDP-323 lowered viral load area under the curve (AUC) by 85% at the high dose and 87% at the low dose compared to placebo.

Those reductions caused the trial to meet its primary endpoint. Enanta also reported hits on two of the secondary endpoints. The biotech linked the two doses of EDP-323 to reductions in viral culture AUC of 98% and 97% compared to placebo; and to symptom reductions of 66% on the high dose and 78% on the low dose, again compared to placebo.

[ ... ]

[chica1] 26/9/2024 15:45

Conserv Bioscience wins innovative award..for those who don't know Hvivo owns a 49%(ish) stake thru Imutex.

www.thisisoxfordshire.co.uk/news/24589682.community-business-celebrated-cherwell-business-awards-2024/

[yump] 26/9/2024 15:37

Extreme weather events continue but its all part of His plan. Choose whatever Him you like, they’re all as “benevolent221; as each other.